TNB-486 Elicits 91% CR Rate in Heavily Pretreated, High-Risk Follicular Lymphoma
TNB-486 demonstrated sustained antitumor activity in all but 1 patient with relapsed/refractory follicular lymphoma, regardless of CD20 status, as well as number and type of prior therapy.
North Carolina United States Bryan Jacobs Tocilizumab Actemra Levine Cancer Institute Atrium Health In Charlotte
Source: onclive.com